+351 211 369 829 INFO@OPHIOMICS.COM

Ophiomics wins the SME Instrument Phase I

Ophiomics was granted the SME Instrument Phase I grant to conduct a Feasibility study for its HepatoPredict genomic signature for Liver Cancer. Check here for the CORDIS page.  This grant will permit Ophiomics to build a business case for HepatoPredict.

Share the Post:

Related Posts

Thinking Big!

Ophiomics is now participating in the IPOready program by Euronext. This is a great opportunity to consider the best strategy

Read More